Clotilde Guidetti

Papers

Total Citations

H-Index

About

Clotilde Guidetti is a clinical researcher whose work centers on novel pharmacological interventions for treatment-resistant psychiatric conditions, with a particular focus on major depressive disorder (MDD) and dissociative symptoms. Her most cited study, "REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants" (2022, 6 citations), represents a significant contribution to the field by exploring the rapid-acting potential of esmethadone beyond its antidepressant effects. This work addresses the critical, often overlooked comorbidity of dissociative disorders in psychiatric populations—which affect nearly 29% of outpatients yet remain vastly underdiagnosed, with only 5% receiving prior identification. Guidetti’s research highlights the urgent need for targeted treatments that can alleviate both depressive and dissociative symptoms simultaneously, offering hope for patients who have not responded to conventional therapies. Her findings underscore the importance of recognizing dissociative states in treatment-resistant depression and pave the way for future investigations into glutamatergic modulation as a therapeutic strategy. Through this work, Guidetti has established herself as a researcher dedicated to improving outcomes for some of the most challenging and underserved patient populations in psychiatry.